Scarica l'app Stockscreener
4.05
1.46%
0.05
Precedente Chiudi:
$4.00
Aprire:
$4
Volume 24 ore:
13,747
Relative Volume:
0.11
Capitalizzazione di mercato:
$55.31M
Reddito:
-
Utile/perdita netta:
$-59.52M
Rapporto P/E:
-0.9194
EPS:
-4.4049
Flusso di cassa netto:
$-51.87M
1 W Prestazione:
-7.34%
1M Prestazione:
+52.57%
6M Prestazione:
+61.69%
1 anno Prestazione:
-14.38%
Intervallo 1D:
$4.00
$4.05
Intervallo di 1 settimana:
$3.60
$4.75
Portata 52W:
$1.70
$4.90
Onkure Therapeutics Inc Stock (OKUR) Company Profile
Nome
Onkure Therapeutics Inc
Settore
Industria
Telefono
(720) 307-2892
Indirizzo
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
Compare OKUR vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OKUR
Onkure Therapeutics Inc
|
4.045 | 54.69M | 0 | -59.52M | -51.87M | -4.4049 |
VRTX
Vertex Pharmaceuticals Inc
|
452.38 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
754.66 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
329.83 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
687.64 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.26 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-30 | Iniziato | Evercore ISI | Outperform |
| 2024-12-05 | Iniziato | Leerink Partners | Outperform |
| 2024-10-10 | Iniziato | Oppenheimer | Outperform |
| 2023-12-15 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-12-15 | Downgrade | Jefferies | Buy → Hold |
| 2023-12-15 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2023-12-14 | Downgrade | BofA Securities | Buy → Underperform |
| 2023-12-14 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2023-12-14 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-12-14 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2023-12-14 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-11-15 | Iniziato | William Blair | Outperform |
| 2023-08-28 | Iniziato | H.C. Wainwright | Buy |
| 2023-07-03 | Iniziato | BofA Securities | Buy |
| 2022-09-19 | Ripresa | H.C. Wainwright | Buy |
| 2022-01-27 | Iniziato | Robert W. Baird | Outperform |
| 2021-12-21 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-22 | Iniziato | Ladenburg Thalmann | Buy |
| 2021-05-04 | Iniziato | Jefferies | Buy |
| 2021-05-04 | Iniziato | Piper Sandler | Overweight |
| 2021-05-04 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Onkure Therapeutics Inc Borsa (OKUR) Ultime notizie
OnKure Therapeutics, Inc. (NASDAQ:OKUR) Short Interest Down 85.2% in March - MarketBeat
OnKure Therapeutics CFO Leverone sells $1.2k in shares - Investing.com UK
OnKure Therapeutics CFO Leverone sells $1.2k in shares By Investing.com - Investing.com Australia
OnKure Therapeutics CEO Saccomano sells $357 in stock By Investing.com - Investing.com Australia
OnKure Therapeutics CEO Saccomano sells $357 in stock - Investing.com
If You Invested $1,000 in OnKure Therapeutics (OKUR) - Stock Titan
OKUR SEC FilingsOnKure Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Published on: 2026-03-19 04:03:55 - baoquankhu1.vn
OnKure reports nearly $60M cash on hand as drug trials continue - BizWest
HC Wainwright Has Positive Forecast for OKUR Q1 Earnings - MarketBeat
OnKure Therapeutics (NASDAQ:OKUR) Price Target Lowered to $27.00 at HC Wainwright - Defense World
OnKure Therapeutics (OKUR): HC Wainwright & Co. Adjusts Price Ta - GuruFocus
H.C. Wainwright cuts OnKure stock price target to $27 on funding By Investing.com - Investing.com South Africa
H.C. Wainwright cuts OnKure stock price target to $27 on funding - Investing.com
Wall Street Zen Upgrades OnKure Therapeutics (NASDAQ:OKUR) to Hold - Defense World
OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - Sahm
OnKure Therapeutics, Inc. 2025 Annual Report: Precision Oncology Pipeline and Focus on PI3Kα Inhibitors - Minichart
Onkure Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Breast cancer trial data and $59M cash: inside OnKure's 2026 pipeline plans - Stock Titan
OnKure Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Can OnKure Therapeutics Inc deliver consistent EPS growth2025 Market Trends & Accurate Intraday Trading Signals - baoquankhu1.vn
Onkure Therapeutics Inc expected to post a loss of $1.15 a shareEarnings Preview - TradingView
OKUR PE Ratio & Valuation, Is OKUR Overvalued - Intellectia AI
Pullback Watch: What is the PEG ratio of OnKure Therapeutics IncJuly 2025 Macro Moves & Weekly High Potential Stock Alerts - baoquankhu1.vn
Why OnKure Therapeutics Inc. stock appeals to dividend seekersWeekly Investment Recap & Expert Approved Trade Ideas - mfd.ru
[SCHEDULE 13G] OnKure Therapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan
OnKure Therapeutics, Inc. (NASDAQ:OKUR) Short Interest Up 43.6% in January - Defense World
Is OnKure Therapeutics Inc. stock oversold or undervaluedJuly 2025 Rallies & Community Trade Idea Sharing Platform - mfd.ru
EV Market: Should I set a stop loss on OnKure Therapeutics Inc2025 Risk Factors & Reliable Price Breakout Signals - baoquankhu1.vn
Is OnKure Therapeutics Inc. in a bullish channelJuly 2025 Technicals & Technical Entry and Exit Tips - mfd.ru
Top Entero Therapeutics (GRDX) Competitors 2026 - MarketBeat
Published on: 2026-01-29 15:39:37 - mfd.ru
Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG), OnKure Therapeutics (OKUR) and Praxis Precision Medicines (PRAX) - The Globe and Mail
Why OnKure Therapeutics Inc. stock could be next big winnerShort Interest Overview & High Yield Trading Alerts - bollywoodhelpline.com
Analyzing Nautilus Biotechnology (NASDAQ:NAUT) and OnKure Therapeutics (NASDAQ:OKUR) - Defense World
OnKure Therapeutics, Inc. (NASDAQ:OKUR) Receives Average Rating of “Hold” from Analysts - Defense World
Published on: 2026-01-11 10:53:08 - Улправда
Targets Report: How risky is OnKure Therapeutics Inc stock nowEarnings Recap Summary & Weekly Sector Rotation Insights - Bộ Nội Vụ
How OnKure Therapeutics Inc. stock performs in weak economyEarnings Overview Report & Daily Market Momentum Tracking - Улправда
Geopolitics Watch: How risky is OnKure Therapeutics Inc. stock nowMarket Sentiment Review & Detailed Earnings Play Strategies - Улправда
Bear Alert: Will OnKure Therapeutics Inc stock attract ESG investorsFed Meeting & Weekly High Momentum Picks - Bộ Nội Vụ
Rally Mode: Why OnKure Therapeutics Inc. stock could be next big winnerJuly 2025 Snapshot & Safe Entry Trade Reports - Улправда
How OnKure Therapeutics Inc. stock performs after earnings - ulpravda.ru
What hedge fund activity signals for OnKure Therapeutics Inc. stock2026 world cup usa national team quarterfinals key players high defensive line odds analysis insights - ulpravda.ru
Will OnKure Therapeutics Inc. stock attract more institutional investors2026 world cup usa national team third place match playmakers high defensive line expert forecast expert opinion - ulpravda.ru
Quarterly Recap: How British Land Company PLC BLD stock expands through international marketsFed Meeting & AI Forecasted Entry and Exit Points - moha.gov.vn
Bull Bear: Why OnKure Therapeutics Inc stock is a must watch in 2025Weekly Profit Report & Low Risk Entry Point Tips - moha.gov.vn
OnKure Therapeutics, Inc. (NASDAQ:OKUR) Short Interest Up 25.6% in December - Defense World
OnKure Therapeutics CEO Saccomano sells $258 in stock By Investing.com - Investing.com India
OnKure Therapeutics Inc Stock Analysis and ForecastDay Trading Setups & Identify Winning Stocks - earlytimes.in
Onkure Therapeutics Inc Azioni (OKUR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Onkure Therapeutics Inc Azioni (OKUR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Leverone Jason A. | Chief Financial Officer |
Mar 23 '26 |
Sale |
4.16 |
301 |
1,251 |
16,000 |
| Saccomano Nicholas A | President and CEO |
Dec 22 '25 |
Sale |
2.97 |
87 |
258 |
7,419 |
| Leverone Jason A. | Chief Financial Officer |
Dec 22 '25 |
Sale |
2.97 |
302 |
896 |
16,301 |
| Saccomano Nicholas A | President and CEO |
Sep 22 '25 |
Sale |
2.62 |
88 |
231 |
3,506 |
| Leverone Jason A. | Chief Financial Officer |
Sep 22 '25 |
Sale |
2.62 |
303 |
795 |
12,603 |
| Saccomano Nicholas A | President and CEO |
Jun 23 '25 |
Sale |
2.38 |
88 |
210 |
3,594 |
| Leverone Jason A. | Chief Financial Officer |
Jun 23 '25 |
Sale |
2.38 |
303 |
722 |
12,906 |
| Cormorant Asset Management, LP | Former 10% Owner |
May 15 '25 |
Sale |
1.85 |
1,813,439 |
3,363,023 |
0 |
| ACORN BIOVENTURES, L.P. | 10% Owner |
May 15 '25 |
Buy |
1.85 |
1,129,730 |
2,090,000 |
1,129,730 |
| ACORN BIOVENTURES, L.P. | 10% Owner |
May 15 '25 |
Buy |
1.85 |
270,270 |
500,000 |
1,709,944 |
0.99%
3.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):